INDIANAPOLIS, March 5, 2024 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego.
The presentations will include new preclinical data for a fully human monoclonal anti-Nectin-4 antibody conjugated to a novel topoisomerase I inhibitor and a highly potent and orally administered inhibitor of KRAS G12D that is selective against wild-type KRAS. In addition, preclinical data on a potent and selective BRM (SMARCA2) inhibitor for the treatment of BRG1 (SMARCA4) mutated cancers will be presented in collaboration with Foghorn Therapeutics. Investigational New Drug (INDs) applications are planned for all three programs in 2024.
Details on poster presentations are below:
Presentation Title: A next generation treatment for Nectin-4 positive cancers – Preclinical characterization of LY4052031, an anti-Nectin-4 antibody, conjugated to a novel camptothecin payload
Abstract Number: 1872
Session Date & Time: Monday, April 8, 9:00 a.m. – 12:30 p.m. PT
Session Title: Antibody-Based Technologies and New Inhibitors
Presenter: Divya Sagar
Presentation Title: LY3962673, an oral, highly potent, mutant-selective, and non-covalent KRAS G12D inhibitor demonstrates robust anti-tumor activity in KRAS G12D models
Abstract Number: 3316
Session Date & Time: Monday, April 8, 1:30 p.m. – 5:00 p.m. PT
Session Title: Novel Antitumor Agents 3
Presenter: Xueqian Gong
Presentation Title: Discovery of selective BRM (SMARCA2) ATPase inhibitors for the treatment of BRG1 (SMARCA4) mutant cancers
Abstract Number: 3230
Session Date & Time: Monday, April 8, 1:30 p.m. – 5:00 p.m. PT
Session Title: Epigenetic Targets
Presenter: Janice Lee
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer’s disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram and LinkedIn. P-LLY
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly’s oncology pipeline, including therapies under development, and reflects Lilly’s current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that studies will be initiated or completed as planned, that future study results will be consistent with the results to date, or that any of these therapies will receive initial regulatory approvals or approvals for additional indications, as applicable, or be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly’s expectations, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
SOURCE Eli Lilly and Company
